Evidence map›Paper›PMID 31125802›Full record

SynthesisThe International journal on drug policy2019

Prevalence of HIV, HCV and HBV infection and sociodemographic characteristics of people who inject drugs in China: A systematic review and meta-analysis.

Yanping Bao, Sarah Larney, Amy Peacock, Samantha Colledge, Jason Grebely, Matthew Hickman, Louisa Degenhardt, Janni Leung

Abstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in The International journal on drug policy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. [Expert recommendations on screening, testing and management for hepatitis B virus infection in adults].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024
    Article
  10. Review
  11. Article
  12. Article
  13. [Hepatitis C elimination among drug users in China: challenges, strategies and experiences].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022
    Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Plasma Inflammatory Biomarkers Associated with Advanced Liver Fibrosis in HIV-HCV-Coinfected Individuals.International journal of environmental research and public health · 2020
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yanping BaoNational Institute on Drug Dependence, Peking University, Beijing, China; National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, Australia.
Sarah LarneyNational Drug and Alcohol Research Centre, UNSW Sydney, Sydney, Australia.
Amy PeacockNational Drug and Alcohol Research Centre, UNSW Sydney, Sydney, Australia.
Samantha ColledgeNational Drug and Alcohol Research Centre, UNSW Sydney, Sydney, Australia.
Jason GrebelyThe Kirby Institute, UNSW Sydney, Sydney, NSW, Australia.
Matthew HickmanPopulation Health Science, Bristol Medical School, University of Bristol, Bristol, UK.
Louisa DegenhardtNational Drug and Alcohol Research Centre, UNSW Sydney, Sydney, Australia.
Janni LeungNational Drug and Alcohol Research Centre, UNSW Sydney, Sydney, Australia; Centre for Youth Substance Abuse Research, The University of Queensland, Brisbane, Australia. Electronic address: j.leung1@uq.edu.au.

Funding

Using existing data to understand and ameliorate risk in opioid agonist therapyR01DA044170 · NIDA · UNIVERSITY OF NEW SOUTH WALES · PI DEGENHARDT, LOUISA · 2017 to 2019
$641k
Department of Health RP-DG-0610-10055Department of Health RP-PG-0616-20008NIDA NIH HHS R01 DA044170
6 · The paper itself

Abstract

backgroundGlobally, China is the largest country by population and contributes substantially to the burden of people who inject drugs (PWID). The aims of this study were to estimate the prevalence of HIV, hepatitis C virus (HCV) and hepatitis B virus (HBV) among PWID at the national and subnational level in China and examine characteristics of PWID.

methodsWe undertook a systematic review of studies published from 2008 to 2017 on HIV, HCV, and HBV seroprevalence among PWID, and characteristics of PWID in Mainland China, Hong Kong, Macao and Taiwan. Meta-analyses were conducted to generate pooled prevalence estimates by province, region, and nationally.

resultsEighty-five papers were included. The pooled HIV, HCV antibody and HBV prevalence among PWID in China was 10.5% (95% confidence interval [95%CI]: 8.6%-12.5%), 71.6% (65.7%-77.6%) and 19.6% (13.7%-25.5%), respectively. In Mainland China, HIV prevalence was highest in the Southwest (14.4%, 10.5%-18.4%) and lowest in the North (1.3%, 0.4%-3.4%). Xinjiang Province had the highest HIV prevalence (42.6%, 35.5%-49.8%). HCV antibody prevalence was highest in the Southwest (77.7%, 69.9%-85.4%), followed by South (76.2%, 65.9%-86.4%). Sichuan had the highest HCV antibody prevalence (91.7%, 86.6%-95.3%), followed by Guangxi (86.1%, 81.8%-90.4%). HBsAg prevalence among PWID was highest in South (25.3%, 14.6%-36.0%), followed by Central (20.8%, 17.4%-24.1%). HBsAg prevalence ranged from 2.4% (0.6-5.9%) in Guizhou to 40.0% (33.7%-46.6%) in Shannxi Province. In China, women and young people accounted for 21.3% and 23.1% of PWID, respectively. It was estimated that 96.1% of PWID injected opioids mainly, and recent injecting risk and sexual risk was reported by 28.5% and 36.7%.

conclusionThere is a large burden of HIV, HCV and HBV prevalence among PWID in China, with considerable geographic variation. The disease burden of viral hepatitis is particularly high, implying that effective management should be integrated into harm reduction interventions among PWID in China.

Indexed as

ChinaComorbidityHepatitis BHepatitis CHIV InfectionsHumansPrevalenceRisk FactorsSubstance Abuse, IntravenousChinaHBVHCVHIVMeta-analysisPeople who inject drugs

Identifiers

PMID31125802
PMCPMC6679982

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.